Want to join the conversation?
During 1Q16, $MYL's largest contributing segment Generics third party net sales increased 17% to $1.93Bil compared to the prior year period, helped by higher sales in North America, Europe and Rest of World. Specialty segment third party net sales rose 17% during 1Q16 helped by higher net sales of the EpiPen Auto-Injector due to higher volumes.
Any idea why some investors are happy about the disastrous $UA results??
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.